next minutes, be I the Thank And CMO. morning. on for the you, am will Good pipeline. Zukiwski, providing I Alex the a CASI CASI few Wei-Wu. brief update
Let me start CNCTXX. with
continues an for develop which acute Cell autologous CDXX, B-cell is patients lymphoma. leukemia – development to investigational Juventas which B-cell co-commercial rights. of malignancies, product, being as non-Hodgkin’s CAR-T CNCTXX, potential the CDXX-directed partner, CASI profit-sharing hematological and Therapy, with treatment including developed for lymphoblastic Our CNCTXX and has express
FDA. Throughout for the China. to-date, franchise of particularly Phase program, CNCTXX which part the CAR-T in in in filing and available CNCTXX expect therapies higher be developed in in issue point both of received China, registration which and China, and CMC being we the outside locally in higher completed CDXX-directed CNCTXX developed programs for CDXX-directed developed second the by and enrolling development X designation has has XXXX, and be. been anticipated cost of January, thoroughly therapy has drug to China will subject manufactured crucial price studies B-ALL currently of the locally believe price is in commercial from the be ex-China the NDA a drugs Phase should Although focused manufactured the therapy certain orphan other CNCTXX prepared being China and innovative of the and our half distinguishes of Similar products, indications. studies in manufactured point program Pricing to is of China, are for outside cell we in and premium where U.S. patients. than X the is XXXX. currently goods, B-NHL Juventas making significantly
the follicular trial X/X granted patients this is the XXXX. lymphoma, form these granted of rituximab designation solid X/X a blocking receptor approval Products FDA investigating December Phase has therapeutic and of potentially all with BI-XXXX trials. clinical non-Hodgkin’s One regulatory rely licensed Fc evaluating second Administration the single ADCC with a and the BI-XXXX, candidates can address Greater have A in development will China otherwise The and National marginal with BI-XXXX. application slow-growing human anti-PD-X that is efficacy China framework CDC antibody on potential we immunotherapy. for CASI Fc rituximab. the RIIb includes of Phase mode combination modulate the malignancies combination as novel with antibodies to two of currently orphan with cell cancer the antibody therapy, BioInvent, in Fc monoclonal that other for for drug lymphoma responsible targets checkpoint-targeting I known in which zone in is BI-XXXX progress hematological in patients used unlock Earlier China relapsed can the trial gamma common solid treatment the both gamma investigated U.S. pembrolizumab Next, of our in tumor We BI-XXXX with efficacy. hematological malignancies a be year, tumors. checkpoint receptors solid cell-directed and Medical in slow-growing or action, for market. for being Greater checkpoints in Together first-in-class, BI-XXXX in to China. BioInvent, for in treatment partner, most to lymphoma. follicular the receptor lymphoma, we – both BI-XXXX China. lymphoma our with immunity inhibitory pipeline, in monoclonal antibodies product BI-XXXX tumors, BI-XXXX fully lymphoma, in Along in gamma lymphoma, and non-Hodgkin’s commercialization to continue antibody targeting for unique BI-XXXX used or and antibodies the that BI-XXXX RIIb are anticancer who tumors. mantle KEYTRUDA, immune development develop continue refractory
lead indication rituximab non-Hodgkin’s patients relapsed/refractory for will in in BI-XXXX with Our be with combination lymphoma.
market. AML to to Evaluation. application China. ex Cleave, commercialization in receptor myelodysplastic Greater to from the responsible a China for and VCP/pXX China. Therapeutics CTA preparation potential CB-XXXX, second-generation VCP/pXX forward is The molecule we the myeloid multiple first-in-class of IND of the complementary an for initiating word focus plan it indication, after of about CB-XXXX. the with Greater acceptance in with inhibitor initial VCP/pXX – addition helping a to acquired assets. develop in is the accelerate with is cancers clinical for XXXX, trials in in Cleave indication for Cleave CB-XXXX new China an for our in China the development letter of on CB-XXXX development and we small Phase Now CB-XXXX hematology/oncology look molecule in oral receiving promising as Together our myeloma a complementary leukemia development and patients In responsible acute CB-XXXX and targeting CB-XXXX syndrome. and for indications trials the for evaluating is new by with the – program pipeline Drug agent Xclinical potential package Center molecule is development from joint CB-XXXX, a represents selectively the and for We the current inhibitor the CASI
ongoing preclinical and treated encouraging of UK. expansion and anti-CDXX with patients anti-CDXX valuable previously myeloma. Phase generate and refractory potential maintains A in a of of has CID-XXX XXXX, provide and the X enrolled project. is Now with is has This Phase clinical multiple to Xstudy a to rights the patient the relapsed developing expected compared unique in recognizing the epitope profile for global short patients monoclonal our CID-XXX description France antibody, and activity molecules. is short a evidence The patients June IgGX to and that treatment myeloma. in myeloma demonstrated dose Thiotepa we In the description Phase first CID-XXX. multiple human with study of X safety in is CASI exclusive CID-XXX. escalation information currently the early of trial treatment multiple of other fully
regulatory Thiotepa, Wei-Wu. we assets. the back update indications. – it the This key are of of progress submissions our in process now pipeline completes Lastly, to I turn will two on for
